Shots:

• CureVac to receive $90.14M up front- $90.14M as milestones on the achievement of specific milestones. GSK will be the marketing authorization holder for the vaccine (Ex-Switzerland) and will have exclusive rights in all countries except Germany- Austria and Switzerland
• Additionally- GSK will support the manufacture of ~100M doses of CureVac’s first generation COVID-19 vaccine candidate CVnCoV in 2021
• The development program will begin imminently- with the target of introducing the vaccine in 2022- subject to regulatory approval

 ­ Ref: GSK | Image: GSK